Century Therapeutics, Inc. — Form 8-K
Filed October 2, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 52/100
What the filing says
Century Therapeutics presented preclinical data for CNTY-813, its iPSC-derived islet cell therapy for type 1 diabetes, at EASD 2026. Data demonstrated: scalable manufacturing across five clinical-scale batches with consistent product profiles; sustained glycemic control in diabetic mice for 11+ months until graft removal; successful engraftment via hepatic portal vein injection in rats; functional product after 96-hour cold storage; and immune evasion via Allo-Evasion 5.0 engineering (HLA knockout, NK inhibitory ligand insertion, IgG-degrading enzyme). IND submission remains on track for Q4 2026, with initial clinical data anticipated in H2 2027. No regulatory or financial transactions occurred; this is a preclinical milestone announcement.
Why this rating
Positive preclinical progress de-risks lead program; on-track IND/clinical timeline material to $212M biotech. But no revenue, partnership, or funding event. Routine milestone.
See more from October 2, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.